Wockhardt’s Zaynich® Shows 97% Efficacy Against Carbapenem-Resistant Infections

Wockhardt Limited informed the exchanges that in a groundbreaking clinical study, Zaynich® demonstrated exceptional efficacy, with over 97% clinical success in treating patients with infections caused by carbapenem-resistant Gram-negative pathogens, including meropenem-resistant strains.

Zaynich® is Wockhardt’s novel proprietary antibiotic that combines Zidebactam and Cefepime (WCK 5222).

The study addressed severe infections such as hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), bloodstream infections (BSI), complicated intra-abdominal infections (cIAI), and complicated urinary tract infections (cUTI). For bloodstream infections, HABP/VABP, and cIAI, Zaynich® achieved a remarkable 100% clinical efficacy.

High Efficacy and Pathogen Eradication Rates

Zaynich® also achieved notable pathogen eradication rates, including 91% for HABP/VABP and 100% for bloodstream infections. The study included critically ill patients across 15 tertiary care hospitals in India, focusing exclusively on carbapenem-resistant Gram-negative infections caused by pathogens like Acinetobacter spp., Pseudomonas spp., Klebsiella spp., and E. coli.

Using advanced molecular diagnostic technologies, the study highlighted Zaynich®’s effectiveness even against extensively drug-resistant (XDR) infections. Treatment durations ranged from 7 to 21 days, with the protocol receiving approval from the Drugs Controller General of India (DCGI).

Addressing the Global Threat of Antimicrobial Resistance

Zaynich® emerges as a game-changer in the fight against antimicrobial resistance (AMR), a growing global threat. Unlike current options such as colistin and polymyxins, which have significant toxicity and limited efficacy, Zaynich® provides a safer and more effective alternative.

It targets critical Gram-negative pathogens identified by the CDC and WHO, making it a valuable tool in combating life-threatening infections. With over 100 critically ill patients saved through its compassionate use in India and the US, Zaynich® sets a new benchmark for treating drug-resistant infections, offering hope for improved patient outcomes worldwide.

On January 13, 2025, Wockhardt share price (NSE: WOCKPHARMA) opened at ₹1,380.00, touching the day’s high at ₹1,442.00, as of 9:58 AM on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.